889 results on '"Hemnes, Anna R."'
Search Results
52. Abstract 15800: Inter-race and Ethnicity Comparisons in Pulmonary Hypertension From the Pulmonary Vascular Phenomics (PVDOMICS) Program
53. Abstract 15433: The Left Atrium and Pulmonary Vascular Disease in PVDOMICS Cohorts
54. Abstract 15029: Atrial Arrhythmias and Pulmonary Hypertension Across Wsph Groups
55. Abstract 14817: Assessing the Burden of Cardiovascular Risk Factors and Disease Across PVDOMICS Cohorts
56. Abstract 14783: Association of Daily Step Count and Resting Heart Rate With Right Ventricular Function in Pulmonary Arterial Hypertension
57. Update on chronic thromboembolic pulmonary hypertension
58. Reply to: Epoprostenol and Treprostinil: Differential Effects on Regulatory T Cell Generation in Patients with Pulmonary Arterial Hypertension
59. Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)
60. Access to Medically Necessary Reproductive Care for Individuals with Pulmonary Hypertension
61. Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension
62. Women’s Health and Lung Development and Disease
63. Valsalva Maneuver in Pulmonary Arterial Hypertension: Susceptibility to Syncope and Autonomic Dysfunction
64. The Use of Embryonic Stem Cells and Induced Pluripotent Stem Cells to Model Pulmonary Arterial Hypertension
65. Pathogenesis of Pulmonary Arterial Hypertension
66. Parenteral Prostanoid Use at a Tertiary Referral Center: A Retrospective Cohort Study
67. Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease: Insights From the PVDOMICS Program
68. Moment on the Lips, a Lifetime on the Lungs?: Improving Models of Group 2 Pulmonary Hypertension
69. Genetic counselling and testing in pulmonary arterial hypertension:a consensus statement on behalf of the International Consortium for Genetic Studies in PAH
70. Myeloid Cell-Derived IL1β Contributes to Pulmonary Vascular Remodeling in Heart Failure with Preserved Ejection Fraction
71. Molecular Function and Contribution of TBX4 in Development and Disease
72. Effect of Acute Arteriolar Vasodilation on Capacitance and Resistance in Pulmonary Arterial Hypertension
73. Disruption of lineage specification in adult pulm mesenchymal progenitor cells promotes microvascular dysfunction
74. Right Ventricular Pathobiology
75. Expression of mutant bone morphogenetic protein receptor II worsens pulmonary hypertension secondary to pulmonary fibrosis
76. Right ventricular protein expression profile in end-stage heart failure
77. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute
78. Use of pulmonary arterial hypertension–approved therapy in the treatment of non–group 1 pulmonary hypertension at US referral centers
79. Prognostic value of acute vasodilator response in pulmonary arterial hypertension: Beyond the “classic” responders
80. Classification and Predictors of Right Ventricular Functional Recovery in Pulmonary Arterial Hypertension
81. Acute vasoreactivity testing during right heart catheterization in chronic thromboembolic pulmonary hypertension: Results from the pulmonary vascular disease phenomics study
82. S-12-4: CITE-SEQ IDENTIFIES TREM2-DEPENDENT GENE PROGRAM DRIVING CARDIAC REMODELING IN A HYPERTENSIVE MODEL OF HEART FAILURE WITH PRESERVED EJECTION FRACTION
83. Transpulmonary generation of cell‐free hemoglobin contributes to vascular dysfunction in pulmonary arterial hypertension via dysregulated clearance mechanisms
84. Elevation of Plasma Cell-Free Hemoglobin in Pulmonary Arterial Hypertension
85. Causes of Pulmonary Hypertension in the Elderly
86. Variability in hemodynamic evaluation of pulmonary hypertension at large referral centers
87. Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension
88. EIF2AK4 Mutations in Pulmonary Capillary Hemangiomatosis
89. Metabolomic Differences in Connective Tissue Disease–Associated Versus Idiopathic Pulmonary Arterial Hypertension in the PVDOMICS Cohort.
90. Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
91. CLINICAL FEATURES DO NOT IDENTIFY RISK OF PROGRESSION FROM ISOLATED POSTCAPILLARY PULMONARY HYPERTENSION TO COMBINED PRE-/POST-CAPILLARY PULMONARY HYPERTENSION
92. Combination Therapy in Pulmonary Arterial Hypertension
93. Prostanoids But Not Oral Therapies Improve Right Ventricular Function in Pulmonary Arterial Hypertension
94. Shorter survival in familial versus idiopathic pulmonary arterial hypertension is associated with hemodynamic markers of impaired right ventricular function
95. Reproducibility of intracardiac and transpulmonary biomarkers in the evaluation of pulmonary hypertension
96. Autonomic Nervous System in Pulmonary Arterial Hypertension: Time to Rest and Digest
97. Genetic counselling and testing in pulmonary arterial hypertension -A consensus statement on behalf of the International Consortium for Genetic Studies in PAH
98. Diabetes Mellitus Associates with Increased Right Ventricular Afterload and Remodeling in Pulmonary Arterial Hypertension
99. Abstract 20250: Evidence of Abnormal Hemoglobin Processing and Generation of Cell Free Hemoglobin Across the Pulmonary Vasculature in Human Pulmonary Arterial Hypertension
100. Abstract 16026: Genetic Variation of Oxidative Phosphorylation Genes Associate With Right Ventricular Function in Patients With Pulmonary Arterial Hypertension
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.